Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
60 Degrees PharmaceuticalsSXTP -5.06%44 Debt-to-Equity is 0.03 as of Mar. 2026, which is at its 10-year median of 0.03. GuruFocus rates SXTP with a GF Score™ of 44/100 and a GF Value™ of $1.98 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 965 Biotechnology companies, 60 Degrees Pharmaceuticals ranks better than 81.14% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for 60 Degrees Pharmaceuticals's Debt-to-Equity or its related term are showing as below:
SXTP'
s Debt-to-Equity Range Over the Past 10 Years
Min: -1.27 Med: 0.03 Max: 0.06
Current: 0.03
During the past 6 years, the highest Debt-to-Equity Ratio of 60 Degrees Pharmaceuticals was 0.06. The lowest was -1.27. And the median was 0.03.
SXTP's Debt-to-Equity is ranked better than 81.14% of 965
companies
in the Biotechnology industry
Industry Median: 0.16
vs SXTP: 0.03
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
60 Degrees Pharmaceuticals Debt-to-Equity Related Terms
60 Degrees Pharmaceuticals Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SXTP vs GNPX, GLMD, HCWB: Debt-to-Equity Comparison
For the Biotechnology subindustry, 60 Degrees Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
60 Degrees Pharmaceuticals Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 60 Degrees Pharmaceuticals's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where 60 Degrees Pharmaceuticals's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
60 Degrees Pharmaceuticals (SXTP) has a Debt-to-Equity of 0.03 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on 60 Degrees Pharmaceuticals and its competitors. This is near median its historical median of 0.03. According to the industry distribution chart, 60 Degrees Pharmaceuticals ranks #182 out of 965 companies in the Biotechnology industry, placing it in the top 18.9%.
Is 60 Degrees Pharmaceuticals' Debt-to-Equity too high?
60 Degrees Pharmaceuticals' current Debt-to-Equity of 0.03 is near median its 10-year median of 0.03. The Biotechnology industry median Debt-to-Equity is 0.16. 60 Degrees Pharmaceuticals' value of 0.03 is 81.3% below this industry median. Based on the distribution chart, 60 Degrees Pharmaceuticals ranks #182 out of 965 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, 60 Degrees Pharmaceuticals has a GF Score™ of 44/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does 60 Degrees Pharmaceuticals' Debt-to-Equity compare to GNPX and GLMD?
According to the Biotechnology industry distribution chart, 60 Degrees Pharmaceuticals ranks #182 out of 965 companies for Debt-to-Equity. This places 60 Degrees Pharmaceuticals in the top 19% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.16. 60 Degrees Pharmaceuticals' value of 0.03 is 81.3% below this benchmark. While the company's 10-year median is 0.03 vs. the industry median of 0.16, 60 Degrees Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 60 Degrees Pharmaceuticals's current Debt-to-Equity of 0.03 is 81.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on 60 Degrees Pharmaceuticals and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 60 Degrees Pharmaceuticals's current Debt-to-Equity is 0.03, which is near median its own 10-year median of 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 60 Degrees Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, 60 Degrees Pharmaceuticals (SXTP) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.98, compared to a current price of $1.50 — trading 24.2% below its estimated fair value. The current Debt-to-Equity is 0.03, which is near median its 10-year median of 0.03 and 81.3% below the Biotechnology industry median of 0.16. 60 Degrees Pharmaceuticals' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For 60 Degrees Pharmaceuticals (SXTP), the current Debt-to-Equity is 0.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 60 Degrees Pharmaceuticals (SXTP) Overvalued in 2026?
Based on GuruFocus' analysis, 60 Degrees Pharmaceuticals stock appears to be undervalued.
The current stock price of $1.50 is trading 24.2% below its estimated GF Value™ of $1.98.
GuruFocus considers 60 Degrees Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for SXTP:
Debt-to-Equity: 0.03 (near median its 10-year median of 0.03)
GF Value™: $1.98 vs. price of $1.50 (24.2% below fair value)
Industry Position: 81.3% below the Biotechnology median (#182 of 965)
No single metric tells the full story. See the SXTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.
44GF Score
Get the complete analysis for SXTP
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SXTP has been successfully added to your 
